UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final draft guidance ...

A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...

Use of GLP-1 RAs is associated with reduced postoperative revision following FESS for up to 5 years among patients with CRSwNP and obesity.

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop ...

SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...